Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Paralympian Initiates Advocacy for Eye Care
Paralympian Amy Dixon has founded Vision Without Limits, a nonprofit that trains and employs eye‑care patient advocates. She created the Certified Ophthalmology Patient Advocate (COPA) program with Alchemy Vision, a six‑week online course that leads to certification and Medicare‑reimbursable services. The initiative partners with Lighthouse for the Blind to place visually impaired advocates in major U.S. eye hospitals, targeting 100 placements in its first year. Dixon argues that dedicated advocates improve patient compliance, reduce financial barriers, and generate new revenue streams for ophthalmology practices.
JAMA Study: AI Scribes Deliver Modest EHR Time Savings Across 5 Major Health Systems
Researchers published a JAMA study analyzing 8,581 ambulatory clinicians across five academic health systems, including 1,809 AI‑scribe adopters. AI scribes reduced total EHR time by 13.4 minutes and documentation time by 16 minutes per eight‑hour shift, yielding a modest 0.49‑visit...
‘Vaginal Estrogen as a Face Filler? I Think Not’: Experts Critique the New Skincare Trend
A viral TikTok trend is encouraging users to apply vaginal estrogen cream as a facial filler, citing its purported collagen‑boosting effects. Dermatology experts caution that the practice is off‑label, lacks robust clinical evidence, and may lead to systemic hormone absorption...
From Transparency to Action: Turning Price Data Into Lower Costs
The article argues that emerging price‑transparency data can dramatically lower U.S. health‑care costs if stakeholders use it to choose high‑value providers. It highlights stark price gaps—an MRI ranging from $125 to $2,565 and joint‑replacement fees varying 2.5‑fold across insurers. The...
Under the Magnifying Glass: A Wave of Drug Price Transparency
In late January and early February 2026, three federal initiatives – a Department of Labor proposed rule, the Consolidated Appropriations Act of 2026, and an FTC settlement with Express Scripts – introduced mandatory transparency reporting for pharmacy benefit managers (PBMs)....
Employers Can Now Save by Comparing Health Care Prices
Employers can now tap Hospital Price Transparency (HPT) and Transparency in Coverage (TiC) data to compare actual negotiated rates across carriers and facilities. A pilot by the Purchaser Business Group on Health (PBGH) and Milliman showed that Aetna’s rates for...
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
The Trump administration has postponed filing an appeal against a federal judge’s injunction on RFK Jr.’s vaccine policy overhaul, citing internal debates over election‑year politics. Meanwhile, Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a premium of...
Teva Intensifies Biosimilar Competition with FDA Approval and Dual Filing Acceptance in US and Europe
Teva Pharmaceutical Industries received U.S. FDA approval for its denosumab‑adet biosimilar, covering all approved indications of Amgen’s Prolia, including osteoporosis and bone loss in cancer patients. The company also secured simultaneous acceptance of regulatory filings with the FDA and the...
Esketamine Nasal Spray Shows Rapid, Durable Effectiveness in Treatment-Resistant Depression
New real‑world evidence from the ECHO study confirms that esketamine nasal spray delivers rapid and durable symptom relief for adults with treatment‑resistant depression. In a European‑Israel cohort of 570 patients, average treatment lasted nine months, producing mean MADRS reductions of ‑10.3...
Sending This Newsletter Out Urgently, because the Clock's Ticking on Starmer's Ultimatum...
The blog warns that a critical deadline set by Labour leader Keir Starmer is looming over the escalating resident doctors’ strikes in the UK. The British Medical Association (BMA) is pushing for safer staffing ratios and pay increases, while the...
Amgen, Zai Lab Team up on DLL3; Janux Gets $35M Milestone Payment
Amgen and China‑based Zai Lab have announced a Phase 1b clinical study that combines Amgen’s T‑cell engager Imdelltra with Zai Lab’s experimental antibody‑drug conjugate zocilurtatug pelitecan, targeting the DLL3 protein in aggressive neuroendocrine cancers. The trial will evaluate safety and early...
Ambience Healthcare Launches Chart Chat for Nursing with Cleveland Clinic Pilot
Ambience Healthcare has introduced Chart Chat for Nursing, an EHR‑integrated conversational AI that lets inpatient nurses retrieve patient information with plain‑language queries. The tool debuted in a pilot with Cleveland Clinic, the first health system to test the technology after a...
A Paralyzed Musician Is Using a Brain Implant to Create Music
Research psychologist Galen Buckwalter, paralyzed since age 16, has six brain implants that translate his motor‑cortex activity into musical tones. The implants, each with 64 channels, provide 384 data streams that are decoded into pitch, allowing him to play a...
HNL Lab's Digital Pathology Platform Enables Faster Results and More
HNL Lab Medicine, part of Jefferson Health, digitized its anatomic pathology practice using six Leica GT450 scanners and Proscia’s Concentriq platform. The transition eliminated manual slide transport across a 14‑hospital network, enabling instant case sharing and remote work for pathologists....
Paragon Offshoot Korsana to Go Public in Reverse Merger for Alzheimer's Work
Paragon Therapeutics is spinning out its Alzheimer’s-focused unit, Korsana Biosciences, via a reverse merger that will list the company on a U.S. exchange. The deal, championed by Paragon co‑founder Jonathan Violin, merges Korsana with a publicly traded shell, providing immediate...
EHealth Gives Callers the Regal Treatment
eHealth partnered with Regal to launch Alice, an AI voice agent that handles Medicare Advantage, prescription drug and Medigap enrollment calls. The platform eliminated wait times, delivering zero‑second answer rates and a 27% higher purchase conversion than human screeners. After...
AI Agents Challenge Vendor Control Over Software Use
We’re about to spend the next decade in tech arguing about something that used to feel settled: who actually gets to decide how software is used once it’s deployed. For most of the last 30 years, the answer was straightforward. The...
Rapid Response: How Boston Children’s Hospital Overcame the Stryker Cyberattack
Boston Children’s Hospital faced a massive wiper cyberattack that crippled Stryker’s Vocera communication platform, prompting an immediate, coordinated response. Within 30 minutes the hospital isolated the vendor network and began dismantling the compromised system. By evening, Epic Secure Chat was...
How a 20-Year Old Asthma Drug Is Boosting Food Allergy Research
A 20‑year‑old asthma medication, Xolair (omalizumab), is now accelerating food‑allergy research, especially for peanut sensitivities. Recent clinical trials combined the drug with oral immunotherapy, cutting severe reaction rates by roughly 70 percent. The FDA has recently cleared the first oral...
FDA Confirms Another Recall for Johnson & Johnson’s Impella Heart Pumps
The FDA has issued a Class I recall for Johnson & Johnson MedTech’s Impella purge cassettes, affecting over 33,000 devices. Leaking cassettes can cause low purge pressure, biomaterial ingress, pump stoppage, and potentially patient death. Four serious injuries have been linked to the...
Johns Hopkins Medicine and ATA Launch Interstate Telehealth Initiative
Johns Hopkins Medicine and the American Telemedicine Association have launched the LIFTT Initiative, a three‑year effort to push federal legislation that eases state licensure barriers for telehealth. The program seeks tailored federal pathways that complement, not replace, state oversight, aiming...
IO Biotech Will File for Bankruptcy After Failure of Cancer Vaccine in Key Trial
Danish biotech IO Biotech announced it will file for Chapter 11 bankruptcy after its lead cancer vaccine failed to demonstrate efficacy in a pivotal trial. The vaccine, designed to treat aggressive solid tumors, showed no statistically significant benefit, prompting the...
Partners Seek to Integrate Dental Care Into Nationwide HIE Infrastructure
CareQuest Innovation Partners and federally designated QHIN Kno2 have announced a partnership to embed dental data into the nation’s health‑information‑exchange (HIE) infrastructure. The collaboration targets bidirectional data flow between dental and medical providers, aiming for a production go‑live within six...
Link Found Between Antibiotics and Depression in Pregnancy
A large Japanese cohort of 94,490 pregnant women found a stepwise association between antibiotic use and psychological distress in early‑to‑mid pregnancy. Women who took antibiotics both before conception and after pregnancy recognition faced a 50% higher odds of severe distress...
Multiple CGM Sensors May Be Used with Automated Insulin Delivery
The FDA cleared Medtronic’s MiniMed 780G pump to operate with Abbott’s Instinct CGM sensor, expanding sensor options for automated insulin delivery. A real‑world study of 13,967 U.S. users showed time‑in‑range rose modestly from 75.1% with Guardian 4 to 77% with Instinct. Automated...
Elevance Sidesteps Medicare Advantage Sanctions for Now
Elevance Health avoided immediate Medicare Advantage sanctions after CMS granted a deadline extension to May 30 to correct years of faulty risk‑adjustment data reporting. The regulator had warned that non‑compliance would trigger enrollment bans and communication suspensions for its MA...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
The New Infrastructure of Drug Commercialization
The pharmaceutical commercialization landscape is undergoing a rapid overhaul, driven by heightened government pricing controls, the rise of complex biologics, cell and gene therapies, and advanced data systems. Cold‑chain logistics have become a strategic priority as temperature‑sensitive products proliferate, while...
Lambert–Eaton Myasthenic Syndrome: Early Recognition, Diagnostic Precision, and Therapeutic Advances in Small Cell Lung Cancer
Lambert‑Eaton Myasthenic Syndrome (LEMS) is increasingly recognized as a prodromal marker for small‑cell lung cancer (SCLC), prompting clinicians to screen earlier. Recent advances in auto‑antibody assays and electrophysiological testing have sharpened diagnostic precision, allowing treatment to begin before overt tumor...
$235K Grant Boosts Lifesaving Gear for Pa. Ambulance Service
The Pennsylvania Department of Community and Economic Development awarded a $235,000 grant to the McCandless‑Franklin Park Ambulance Authority. The funds will purchase six LUCAS mechanical chest‑compression devices and a LIFEPAK 35 heart monitor‑defibrillator, which costs about $65,000. Each ambulance will receive...
FDA Threatens Unprecedented Ban Lift on Untested Injectables
If FDA does this, which is highly likely succumbing to pressure from RFK Jr, it crosses a new red line and, as far as I know, is unprecedented. Lifting a ban on drugs that are injected into the bloodstream without...
Lilly's Obesity Drug Cleared, Heats up Novo Rivalry
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk https://t.co/8TyrKyyNYP
Changemaker Awardee: HIMSS Involvement Fosters Career Growth
Cedric Truss, a Georgia State University student, joined HIMSS as a member and progressed to volunteer on multiple HIMSS committees and task forces. His hands‑on involvement gave him industry‑relevant skills, mentorship, and a robust professional network. Today, Truss actively encourages...
PEPFAR Faces Fatal Funding Cuts, Jeopardizing HIV Gains
#PEPFAR, which changed the trajectory of the #HIV epidemic, "is being slowly starved, through budgetary choke points and administrative fiat," at risk of dying a death of a thousand cuts, @sciencecohen reports. https://t.co/RFOXy1Ueql
Stress Directly Triggers Addiction, New Study Shows
Direct Link Between Stress and Addiction Found - https://t.co/rwLwvh4egR via @neurosciencenew #Addiction #mentalhealth #alcohol #substanceusedisorder #health #lifestylemedicine #pavingwellness #HealthyLivingCommunity #WellnessJourney
“When Is the Optimal Moment to Stop Watching the Scoliotic Curve and Operate?”
A European Spine Study Group analysis of 310 adult thoracolumbar idiopathic scoliosis patients identified a quality‑of‑life inflection point between ages 30 and 42, after which pre‑operative SRS‑22 scores decline and rarely catch up to younger post‑operative levels. While earlier surgery...
How 3D Medical Animations Transform Conference Presentations
Medical conferences are saturated with static slide decks that struggle to convey complex mechanisms, leading to audience fatigue and low retention. 3D medical animations replace static visuals with dynamic, motion‑driven storytelling, allowing presenters to illustrate molecular interactions, device usage, and...
STAT+: Insilico Medicine CEO on How Best to Use AI in Drug Development
Insilico Medicine, a veteran AI‑driven drug discovery firm, announced a partnership with Eli Lilly that includes a $115 million upfront payment and up to $2.75 billion in milestone‑based total consideration. The deal leverages Insilico’s generative‑AI platform to co‑develop novel therapeutics, primarily targeting metabolic...
11 Startups Selected for National Life Sciences Accelerator Program
Eleven early‑stage life‑sciences startups were chosen for the Drive accelerator, with eight headquartered in Massachusetts and the remaining three in South Carolina. MassBio will manage the biotech cohort while SCbio leads the biomarkers and diagnostics group. The free eight‑week program...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Voluntary Paid Leave Insurance Is No Substitute for Comprehensive Paid Family and Medical Leave: Workers Lose when Lawmakers Pass the...
U.S. remains the only OECD nation without a national paid family and medical leave (PFML) system, prompting many states to adopt either comprehensive PFML programs or voluntary private‑insurance models. While 13 states and Washington, D.C. have enacted universal PFML laws...
Merging Remote Patient Monitoring (RPM) Into Traditional Care Models
Claiborne Memorial Medical Center in rural Louisiana launched a pilot program that enrolls 22 high‑risk patients in remote patient monitoring (RPM) to supplement its chronic‑care model. By transmitting home‑collected vitals such as blood pressure and glucose readings, clinicians can adjust...
Healthcare Exposure Focused on Big Pharma? You’re Missing Out
The ROBO Global Healthcare Technology & Innovation Index (HTEC) offers investors a research‑driven way to capture disruptive health‑tech across nine subsegments, from robotics to genomics. It moves beyond traditional pharmaceutical or provider classifications by scoring companies on revenue from innovative...
Making Revenue Cycle Work Smarter
Automation, AI, and advanced analytics have moved from optional tools to core components of the healthcare revenue cycle. By targeting repetitive, high‑volume tasks across front‑end eligibility checks, mid‑cycle documentation, and back‑end claims processing, organizations can cut errors, lower denial rates,...
New York State Must Intervene in the Behavioral Health Crisis
New York is confronting a deepening behavioral health crisis, with suicide rates climbing more than 40% over the past 20 years and overdose deaths nearly four times higher than in 2010. Medicaid Managed Care Organizations have extracted hundreds of millions...
Fixing Healthcare Means Trusting Doctors and Patients — Not Payers
Employers are confronting the steepest premium hikes in 15 years, with average family coverage nearing $25,500 and a 10% increase this year. The article argues that the employer‑based insurance model’s built‑in barriers—prior authorizations, narrow networks, and opaque pricing—are features, not...
How to Mitigate Cognitive Risks Decades Early for Women
A recent JAMA Network Open study found that older women with elevated plasma phosphorylated tau 217 (p‑tau217) face a significantly higher chance of developing mild cognitive impairment or dementia up to 25 years later. The biomarker offers clinicians a window for early...
Atlanta Women and Youth Face Rising Mental‑Health Crisis, Report Shows
The Atlanta Women’s Foundation released a study revealing that 90% of women and youth seeking mental‑health services in metro Atlanta report anxiety, with over half facing cost‑burdened housing. The findings highlight economic stress, provider shortages and systemic barriers, prompting calls...
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Q1 2026 biopharma saw a wave of mega‑size M&A, with deals like Boston Scientific’s $14.5 billion purchase of Penumbra and Eli Lilly’s $7.8 billion acquisition of Centessa, underscoring a strategic push for precision platforms. The quarter also delivered a string of rare‑disease approvals—Zycubo,...